Author:
Hao Jiaojiao,Fan Wenhua,Li Yizhuo,Tang Ranran,Tian Chunfang,Yang Qian,Zhu Tianhua,Diao Chaoliang,Hu Sheng,Chen Manyu,Guo Ping,Long Qian,Zhang Changlin,Qin Ge,Yu Wendan,Chen Miao,Li Liren,Qin Lijun,Wang Jingshu,Zhang Xiuping,Ren Yandong,Zhou Penghui,Zou Lijuan,Jiang Kui,Guo Wei,Deng Wuguo
Funder
National Natural Science Foundation of China
the National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Rotte A, Bhandaru M, Zhou Y, McElwee KJ. Immunotherapy of melanoma: present options and future promises. Cancer Metastasis Rev. 2015;34(1):115–28.
2. Wick MR, Gru AA. Metastatic melanoma: pathologic characterization, current treatment, and complications of therapy. Semin Diagn Pathol. 2016;33(4):204–18.
3. Xu X, Jin Z, Liu Y, Gong H, Sun Q, Zhang W, et al. Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8(+) T-cell responses and reduce the immunosuppressive activity of MDSCs. Cancer letters. 2018;440–441:94–105.
4. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer Metastasis Rev. 2017;36(1):43–50.
5. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133–7.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献